ReviewCurrent neurology and neuroscience reports2026
Assessment and Management of Post-traumatic Headache.
Review in Current neurology and neuroscience reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purpose of reviewThe goal of this narrative review is to provide a comprehensive analysis of Post-Traumatic Headache (PTH), addressing its epidemiology, pathophysiology, and multidisciplinary management. The paper seeks to explore the diagnostic controversies surrounding the timing of symptom onset and evaluates current assessment methods and treatment paradigms for this prevalent sequela of traumatic brain injury. RECENT
findingsRecent research highlights that while current diagnostic criteria require headache onset within seven days of injury, delayed-onset symptoms are common, creating a significant diagnostic dilemma. Pathophysiologically, PTH is understood to be multifaceted, driven by neuroinflammation, neurometabolic cascades, and central sensitization. These processes result in clinical phenotypes that often mirror primary migraine or tension-type headaches. Additionally, while clinical history remains the gold standard for assessment, emerging blood biomarkers are showing promise as objective tools for evaluation. The review concludes that PTH management currently requires a multimodal approach, combining non-pharmacological interventions with pharmacological treatments adapted from primary headache protocols. A major takeaway is the lack of high-quality, PTH-specific randomized controlled trials, which currently forces a reliance on expert opinion rather than robust clinical evidence. To improve patient outcomes, future research must shift toward a more multi-disciplinary, patient-centered paradigm and focus on generating high-quality data to move beyond diagnostic controversies and empiric treatment.
Indexed as
Identifiers
41999567What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.